Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review

• Published in: International journal of retina and vitreous Vol. 7; no. 1; p. 37
• Main Authors: Anderson, William J, da Cruz, Natasha Ferreira Santos, Lima, Luiz Henrique, Emerson, Geoffrey G, Rodrigues, Eduardo Büchele, Melo, Gustavo Barreto
• Format: Journal Article
• Language: English
• Published: England BioMed Central 07-05-2021; BMC
• Subjects: Abicipar; Aflibercept; Asymptomatic; Bevacizumab; Clinical trials; Faricimab; FDA approval; Inflammation; Intravitreal injection; Macular degeneration; Monoclonal antibodies; Noninfectious inflammation; Pain; Patients; Pharmaceuticals; Review; Vascular endothelial growth factor; United States > US; San Francisco California; Noninfectious inflammation; Abicipar; Intravitreal injection; Faricimab; Ranibizumab; Silicone oil; Sterile endophthalmitis; Aflibercept; Pegaptanib; Bevacizumab
• ISSN: 2056-9920; 2056-9920
• DOI: 10.1186/s40942-021-00307-7

Intraocular inflammation is an uncommon but potentially vision-threatening adverse event related to anti-VEGF therapy. This is of increasing importance given both the volume of injections performed, as well as the increased prevalence of inflammation seen with newer anti-VEGF agents. Brolucizumab, the newest anti-VEGF agent, has been associated with an inflammatory retinal vasculitis and the underlying mechanism is unclear. Reviewing potential mechanisms and clinical differences of intraocular inflammation may assist clinicians and scientists in reducing the risk of these events in the future.
Two types of inflammation are seen with intravitreal injections, acute onset sterile inflammation and delayed onset inflammatory vasculitis. Acute onset inflammation can be subcategorized into subclinical anterior chamber inflammation and sterile uveitis/endophthalmitis. Subclinical anterior chamber inflammation can occur at rates as high as 19% after intravitreal anti-VEGF injection. Rates of sterile uveitis/endophthalmitis range from 0.05% to 4.4% depending on the anti-VEGF agent. Inflammatory vasculitis is only associated with brolucizumab and occurred in 3.3% of injections according to the post hoc review of the HAWK/HARRIER data. In addition, silicone oil from syringes can induce immunogenic protein aggregates. Agitation of the syringe, freeze thawing, shipping and improper storage prior to injection may increase the amount of silicone oil released from the syringe.
The main factors which play a role in intraocular inflammation after anti-VEGF injection can be divided into three causes: patient-specific, medication-specific and delivery-specific. The majority of clinically significant inflammation seen after intravitreal injection is an acute onset inflammatory response with most patients recovering baseline VA in 3-5 weeks. The presence of pain, hypopyon, severe anterior chamber reaction, hyperemia and significant vision loss may help distinguish infectious from non-infectious etiologies of post injection inflammation. Avoiding temperature fluctuation, mechanical shock, agitation during transport and handling of syringes/drugs, and the use of SO-free syringes may help minimize intraocular inflammation. While a definitive mechanism has not yet been established, current knowledge of the clinical presentation and vitreous histopathology of brolucizumab-retinal vasculitis favors an auto-immune type IV hypersensitivity reaction.